| 产品描述: | LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin and Paclitaxel on ovarian cancer cell formation, migration, and growth. |
| 靶点: |
p-STAT3 |
| 体内研究: |
LLL12 (0.01-1 μM; 72 h) 在顺铂 (0.5 μM, 2.5 μM) 和紫杉醇 (0.25 μM, 0.5 μM) 作用下均能抑制卵巢癌细胞系的细胞活力。 LLL12 (0.25-1.0μM) 抑制卵巢癌细胞系中 STAT3 磷酸化 (Tyr705)。 |
| 参考文献: |
1. Zhang R, et al. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells. Oncol Rep. 2020 Sep;44(3):1224-1232. 2. Onimoe GI, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 2012 Jun;30(3):916-26. |
| 保存条件: |
-80°C 6个月; -20°C 1个月,避光 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.297 ml |
16.486 ml |
32.972 ml |
| 5 mM |
0.659 ml |
3.297 ml |
6.594 ml |
| 10 mM |
0.33 ml |
1.649 ml |
3.297 ml |
| 50 mM |
0.066 ml |
0.33 ml |
0.659 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |